Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Viracor Acquires Exclusive License to Cornell Cell-Free DNA Assay Technology

NEW YORK — Eurofins Viracor said on Thursday that it has acquired an exclusive license to a sequencing-based liquid biopsy technology developed at Cornell University for tracking tissue damage in COVID-19 and transplant patients.

Eurofins Viracor said the technology has been used by its developers to create an assay that can scan for complications of hematopoietic cell transplantation. It can also be used to gauge the damage COVID-19 has on cells, tissues, and organs, as well as to identify the presence of urinary tract infections in kidney transplant patients and assess damage to the kidney and bladder.

The Lee's Summit, Missouri-based company said it intends to use the technology to develop and commercialize assays for all three applications.

Financial and other terms of the license with Cornell were not disclosed.

About a year ago, Eurofins Viracor acquired a license from the Cleveland Clinic for a urine biomarker test for detecting rejection in kidney transplant patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.